Primary liver cancer, i.e., Hepatocellular carcinoma (HCC), is one of the most lethal types of cancer being particularly prevalent in China. Effective treatment is predicated on early detection and radical treatment. However, early diagnosis through population screening, using physical methods(ultrasound), yields suboptimal performance.

​

Together with world-leading HCC experts, we have developed an AI approach to early detection by blood tests, using large datasets and employing machine learning. We have also follow FDA's guideline to develop SaMD and should complete and submit our application by the end of 2024.